TrialAmerican journal of medical genetics. Part A2019

Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.

Derralynn A Hughes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.